Close
0
Inquiry Basket
Hot Products

GlycoErase™ SLC35C1 Knockout Human Prostate Cancer Cell 22RV1

CAT#: GLJF-0525-JF338

Datasheet Request COA
Overview
Description
The SLC35C1-deficient 22RV1 cell line allows investigation of Golgi GDP-fucose transport disruption in prostate cancer, potentially leading to fucosylation defects and impacting fucosylated glycans.
Product Type
KO Cell Lines
Species
Human
Cell Morphology
Epitheloid cells, adherent
Passage Ratio
1:3~1:10
Cell Line
22RV1
Primary Disease
Prostate Adenocarcinoma
Lineage
Prostate
Specification
Cell Viability
>90%
Sterility Test
The sterility test indicated an absence of microbial growth.
Identity Test
STR identification
Mycoplasma Test
Negative
Virus Test
Negative for HIV, HBV and HCV.
Genetic Stability Testing
We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation
PCR, Sanger Sequencing
Culture Medium
DMEM & FBS & RPMI
Application
Functional assay
Size
1 M cells/vial*2
Product Format
Frozen
Shipping
Dry ice
Availability Status
Made to order
Handling Notes
Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer
This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.
Target Information
Target
SLC35C1
Full Name
Solute carrier family 35 member C1
Alternative Name
FLJ11320, FUCT1
Location
11p11.2
Gene ID
Summary
Encodes a GDP-fucose transporter located in the Golgi apparatus; mutations in this gene can disrupt glycosylation processes and lead to congenital disorder of glycosylation type IIc.
For Research Use Only.
Online Inquiry
Copyright © Creative Biolabs. All Rights Reserved.